Residual Neuromuscular Blockade and Adverse Respiratory Outcomes

Glenn S. Murphy, MD
Jeffery S. Vender Chair of Anesthesiology Research and Education
NorthShore University HealthSystem
Clinical Professor
University of Chicago Pritzker School of Medicine
Disclosure Information

I have the following financial relationship to disclose:
Consultant for: Merck & Co., Inc

I will not discuss off-label use and / or investigational use in my presentation
Is residual neuromuscular blockade associated with adverse respiratory outcomes during the early recovery period from anesthesia and surgery?
How Is Residual Neuromuscular Blockade Defined

- With quantitative neuromuscular monitoring
  - MMG, EMG, AMG
  - Traditional definition: TOF ratio < 0.7
  - Based on several studies from 1970’s
  - Current “gold standard”: TOF ratio < 0.9
  - Based on several studies from 1990-Present

- Presence of signs or symptoms of muscle weakness in the postoperative period in patients who received NMBAs
<table>
<thead>
<tr>
<th>Sub-population</th>
<th>Pooled Rate of PORC$^\text{§}$</th>
<th>Confidence Interval</th>
<th>Heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>$P$-value</td>
</tr>
<tr>
<td>Long-acting (TOF&lt;0.7)</td>
<td>0.351</td>
<td>(0.25-0.46)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intermediate-acting (TOF&lt;0.7)</td>
<td>0.115</td>
<td>(0.07-0.17)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Long-acting (TOF&lt;0.9)</td>
<td>0.721</td>
<td>(0.59-0.84)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Intermediate-acting (TOF&lt;0.9)</td>
<td>0.413</td>
<td>(0.25-0.58)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
The RECITE study: A Canadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade

- Prospective observational study of the incidence of PRNB at 8 Canadian hospitals
- ASA I-III patients undergoing abdominal surgery were assessed
- TOF ratios measured immediately before extubation and on arrival to PACU

Results
- 302 patients enrolled
- Rocuronium used in 99% of cases
- Neostigmine reversal used in 73% of cases
- Incidence PRNB: 64% at extubation
  57% at PACU arrival
Residual Neuromuscular Blockade and Adverse Respiratory Events

- Database Studies
  - Large database or observational investigations examining the association between neuromuscular management characteristics and adverse respiratory outcomes

- Clinical Studies
  - Prospective observational trials
  - Randomized clinical trials
Database Studies

● **Advantages**
  - Large size
  - Determine incidence of less common outcomes
  - Frequently multi-institutional

● **Disadvantages**
  - Uncontrolled and not randomized
  - Observational and retrospective studies can only demonstrate *associations*, not causality
  - The presence or absence of residual block was not definitively established using quantitative monitoring
Methods

- Data collected by 10 teams at 10 hospitals over a 5-year period in the United States
- All cases of deaths on the surgical services were examined
- Causes of death were determined by the team at each hospital

Results

- Data collected on 599,548 anesthetics
- Mortality rates when NMBAs were used (1:370) were 6x higher than when NMBAs were avoided (1:2100)
- 63% of the deaths involving NMBAs were caused by respiratory failure
Death Attributable to Anaesthesia: A 10-Year Survey (1967-1976)
Harrison GG. Br J Anaesthesiol 1978; 50: 1041-46

- **Methods**
  - Mortality data collected over 10 years at Groote Schuur Hospital, Cape Town
  - Examined data from 240,483 anesthetics

- **Results**
  - Frequency of death to which anesthesia contributed was 0.22 per 1000 anesthetics
  - Anesthetic deaths were attributed to:
    1. Hypovolemia
    2. *Respiratory inadequacy following myoneural block*
    3. Complications of tracheal extubation
    4. Inadequate postoperative care and supervision
Study conducted by the Association of Anaesthetists of Great Britain and Ireland

Detailed data collected on all deaths that occurred within 6 days of surgery in 1981

2 assessors determined the role of anesthetic management in mortality (entirely, partially, or not all)

Results

32 of 197 (16%) of deaths were judged to be totally due to anesthesia

Single largest clinical cause of anesthesia-related death in the series was:

“postoperative respiratory failure due to neuromuscular management”
7,029 surgical patients prospectively examined to determine risk factors for postoperative pulmonary complications.

Preoperative and intraoperative factors examined.

**Results**

- 290 (4.1%) patients developed a POPC (atelectasis/pneumonia most common).
- Multiple logistic regression analysis revealed that the primary intraoperative risk factor was GA involving pancuronium for procedures ≥180 min (OR 2.64).
Methods

- Prospectively collected data on 24,157 PACU patients who received a GA over a 33-month period
- A critical respiratory event (CRE) defined as unanticipated
  - Hypoxemia
  - Hypoventilation
  - Airway obstruction requiring an intervention
- Patient, surgical, and anesthetic risk factors identified
<table>
<thead>
<tr>
<th>Management</th>
<th>n*</th>
<th>Rate of Critical Respiratory Events</th>
<th>Relative Risk</th>
<th>95% Confidence Interval</th>
<th>Adjusted Relative Odds†</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Premedication</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sedative</td>
<td>2,611</td>
<td>2.0</td>
<td>1.87</td>
<td>(1.37–2.55)</td>
<td>2.00</td>
<td>(1.49–2.69)</td>
</tr>
<tr>
<td>Opioid ± sedative</td>
<td>3,432</td>
<td>2.6</td>
<td>2.51</td>
<td>(1.95–3.23)</td>
<td>1.76</td>
<td>(1.24–2.49)</td>
</tr>
<tr>
<td>No premedication§</td>
<td>17,631</td>
<td>1.0</td>
<td>1.00</td>
<td>—</td>
<td>1.00</td>
<td>—</td>
</tr>
<tr>
<td><strong>Induction Agent</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiopental</td>
<td>18,230</td>
<td>1.6</td>
<td>3.86</td>
<td>(2.5–5.9)</td>
<td>2.46</td>
<td>(1.56–3.89)</td>
</tr>
<tr>
<td>Propofol§</td>
<td>5,158</td>
<td>0.4</td>
<td>1.00</td>
<td>—</td>
<td>1.00</td>
<td>—</td>
</tr>
<tr>
<td><strong>Sedative</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any benzodiazepine</td>
<td>13,634</td>
<td>1.5</td>
<td>1.26</td>
<td>(1.02–1.60)</td>
<td>1.28</td>
<td>(0.99–1.64)</td>
</tr>
<tr>
<td><strong>Inhalational Agent</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enflurane</td>
<td>12,682</td>
<td>1.4</td>
<td>1.09</td>
<td>(0.88–1.36)</td>
<td>‡</td>
<td>‡</td>
</tr>
<tr>
<td>Isoflurane§</td>
<td>9,765</td>
<td>1.4</td>
<td>1.00</td>
<td>—</td>
<td>‡</td>
<td>‡</td>
</tr>
<tr>
<td><strong>Antiemetic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Droperidol ≥ 0.01 mg · kg⁻¹</td>
<td>6,089</td>
<td>1.8</td>
<td>1.36</td>
<td>(1.06–1.73)</td>
<td>1.05</td>
<td>(0.76–1.45)</td>
</tr>
<tr>
<td>Droperidol &lt; 0.01 mg · kg⁻¹</td>
<td>5,433</td>
<td>1.1</td>
<td>0.87</td>
<td>(0.64–1.16)</td>
<td>1.29</td>
<td>(0.97–1.71)</td>
</tr>
<tr>
<td>No droperidol§</td>
<td>12,120</td>
<td>1.3</td>
<td>1.00</td>
<td>—</td>
<td>1.00</td>
<td>—</td>
</tr>
<tr>
<td><strong>Opioid</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Only fentanyl, &gt;1–≤ 2 µg · kg⁻¹ · h⁻¹</td>
<td>8,595</td>
<td>1.1</td>
<td>0.76</td>
<td>(0.58–0.99)</td>
<td>1.07</td>
<td>(0.79–1.43)</td>
</tr>
<tr>
<td>Only fentanyl, &gt;2 µg · kg⁻¹ · h⁻¹</td>
<td>3,529</td>
<td>1.3</td>
<td>0.91</td>
<td>(0.65–1.28)</td>
<td>1.87</td>
<td>(1.26–2.79)</td>
</tr>
<tr>
<td>Fentanyl, morphine combination</td>
<td>1,689</td>
<td>2.8</td>
<td>1.95</td>
<td>(1.40–2.73)</td>
<td>1.55</td>
<td>(1.06–2.92)</td>
</tr>
<tr>
<td>Alternate narcotic choices</td>
<td>1,167</td>
<td>1.3</td>
<td>0.90</td>
<td>(0.53–1.53)</td>
<td>0.98</td>
<td>(0.54–1.77)</td>
</tr>
<tr>
<td>Fentanyl, ≤1 µg · kg⁻¹ · h⁻¹ or nil§</td>
<td>8,694</td>
<td>1.4</td>
<td>1.00</td>
<td>—</td>
<td>1.00</td>
<td>—</td>
</tr>
<tr>
<td><strong>Ventilation/muscle Relaxant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spontaneous—mask</td>
<td>4,620</td>
<td>0.3</td>
<td>0.21</td>
<td>(0.12–0.36)</td>
<td>0.63</td>
<td>(0.34–1.31)</td>
</tr>
<tr>
<td>Spontaneous—tracheal intubation</td>
<td>380</td>
<td>1.8</td>
<td>1.26</td>
<td>(0.60–2.67)</td>
<td>2.21</td>
<td>(0.95–5.13)</td>
</tr>
<tr>
<td><strong>Controlled with</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atracurium, ≥0.25 mg · kg⁻¹ · h⁻¹</td>
<td>1,252</td>
<td>3.4</td>
<td>2.30</td>
<td>(1.61–3.29)</td>
<td>2.17</td>
<td>(1.40–3.34)</td>
</tr>
<tr>
<td>Vecuronium, ≥0.04 mg · kg⁻¹ · h⁻¹</td>
<td>7,844</td>
<td>1.4</td>
<td>0.95</td>
<td>(0.73–1.25)</td>
<td>1.19</td>
<td>(0.87–1.62)</td>
</tr>
<tr>
<td>Pancuronium, ≥0.02 mg · kg⁻¹ · h⁻¹</td>
<td>1,399</td>
<td>2.2</td>
<td>1.52</td>
<td>(0.74–2.01)</td>
<td>1.45</td>
<td>(0.91–2.33)</td>
</tr>
<tr>
<td>Any combination</td>
<td>1,010</td>
<td>1.8</td>
<td>1.22</td>
<td>(1.02–2.26)</td>
<td>1.28</td>
<td>(0.81–2.00)</td>
</tr>
<tr>
<td>Controlled with low-dose§</td>
<td>7,074</td>
<td>1.5</td>
<td>1.00</td>
<td>—</td>
<td>1.00</td>
<td>—</td>
</tr>
<tr>
<td>Atracurium, &lt;0.25 mg · kg⁻¹ · h⁻¹ or</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vecuronium, &lt;0.04 mg · kg⁻¹ · h⁻¹ or</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancuronium, &lt;0.02 mg · kg⁻¹ · h⁻¹ or</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Medical records reviewed on all cardiac arrests that occurred at the Mayo Clinic over a 10-year period (1990-2000)

Data collected on cardiac arrest that occurred after anesthesia initiated in the OR until discharge from the PACU or admission to the ICU

Patient, anesthetic, and surgical factors analyzed

Results

- Cardiac arrest occurred in 223 of 518,294 anesthetics
- 24 patients had arrest primarily related to anesthesia
  - 13 medication-related
  - 11 airway/ventilation-related
  - 9 of the 24 “related to the use of NMBAs or RNMB”
Methods

- Case-control study → identify risk factors related to anesthesia management for mortality or coma within 24 hours of surgery
- Data were collected (1995-1997) on all patients undergoing GA (869,483 patients) in 3 of 12 provinces in The Netherlands
- Cases: Patients who remained comatose or died

Results

- 807 “cases” and 883 matched “controls” were analyzed.
- The most significant risk factor identified in the analysis was related to neuromuscular management
- Reversal of the effects of muscle relaxants was associated with a marked reduction (odds ratio, 0.10; 95% CI, 0.03-0.31) in mortality and coma
Objective: To determine if NMBAs associated with an increased incidence of postoperative respiratory complications (O₂ saturation < 90% or reintubation requiring unplanned admission to the ICU)

Prospective, propensity score matched cohort study (18,579 patients receiving NMBAs matched with 18,579 patients not administered NMBAs) conducted between 2006-2010
<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Not received (n=18,579)</th>
<th>Received (n=18,579)</th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desaturation &lt;90%</td>
<td>689</td>
<td>925</td>
<td>1.36 (1.23 to 1.51)</td>
</tr>
<tr>
<td>Desaturation &lt;80%</td>
<td>128</td>
<td>212</td>
<td>1.66 (1.34 to 2.07)</td>
</tr>
<tr>
<td>Reintubation</td>
<td>108</td>
<td>151</td>
<td>1.40 (1.09 to 1.80)</td>
</tr>
<tr>
<td>In-hospital death</td>
<td>48</td>
<td>55</td>
<td>1.15 (0.78 to 1.69)</td>
</tr>
</tbody>
</table>
Hospital-based registry of 48,499 patients who received NMBA at MGH between 2007-2012

Hypothesis: Higher NMBA use associated with increased risk PoPC

Data collected from AIMS, billing info, and Research Patient Data Registry

PoPC= respiratory failure, PE, re-intubation, pneumonia

Results

1,812 patients (3.7% experienced PoPC)
Total intraoperative NMBAs dose as multiples of median dose required per body weight to achieve 95% reduction in maximal twitch response from baseline in 50% of the population (ED95)
Prospective observational study
3000 patients enrolled
Unwarranted use of neostigmine:
  Neostigmine used in the absence of NM monitoring
  Neostigmine administered at a TOF count of 0
Data collected from 1,444 patients from a single hospital in Australia in 2011

Primary endpoint: Pulmonary complications within 7 days of surgery (scoring system from 0 to 100)

Results

- 722 sugammadex, 212 neostigmine, 510 no reversal
- Pulmonary outcome scores worsened in ASA 3 and 4 patients > 60 years old reversed with neostigmine or given no reversal; no detrimental effect of age on pulmonary outcome scores in patients in sugammadex group (P<0.05)
Conclusions: Neuromuscular Management and Adverse Respiratory Events-Database Studies

- Several large database studies have examined anesthetic-related causes of major morbidity and mortality. Postoperative respiratory failure due to neuromuscular management was the primary cause of adverse outcomes in many of these investigations.
- Limitation: The presence or absence of residual blockade not determined in these investigations.
- Data is suggestive, not conclusive.
Residual Neuromuscular Blockade and Adverse Respiratory Outcomes

Clinical Studies
Residual block measured in PACU → adverse postoperative respiratory events
  - Hypoxemia
  - Airway obstruction
  - PoPC
Objective: To determine whether RNMB after pancuronium or vecuronium results in hypoxemia or hypercarbia in the PACU

- 76 consecutive surgical patients enrolled
- On arrival to PACU, TOF ratios quantified with AMG
- RNMB defined as a TOF ratio < 0.7
Bissinger et al.-Results

- TOF ratio < 0.7:
  - Pancuronium 20%
  - Vecuronium 7%
- No differences between groups in incidence of hypercapnia
Objective: to assess the effect of choice of NMBA (long-or intermediate-acting) on postoperative recovery and respiratory status

Methods
- 70 patients undergoing orthopedic surgical procedures randomized to receive pancuronium or rocuronium
- NM monitoring and reversal used in all subjects
- TOF ratios quantified with acceleromyography (AMG) on arrival to PACU and at + 30 minutes
- Episodes of hypoxemia measured (SpO₂ < 93 or 90%)
Murphy et al. - Results

<table>
<thead>
<tr>
<th>Variable</th>
<th>Rocuronium group</th>
<th>Pancuronium group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Train-of-four ratio &lt; 0.9 at:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PACU arrival</td>
<td>10</td>
<td>29</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>30 min after PACU arrival</td>
<td>1</td>
<td>11</td>
<td>0.003</td>
</tr>
<tr>
<td>Patients having episodes of</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spo₂ &lt; 93%</td>
<td>10</td>
<td>21</td>
<td>0.015</td>
</tr>
<tr>
<td>Spo₂ &lt; 90%</td>
<td>7</td>
<td>15</td>
<td>NS</td>
</tr>
<tr>
<td>Need for oxygen therapy</td>
<td>4</td>
<td>10</td>
<td>NS</td>
</tr>
</tbody>
</table>
Hypothesis: Patients with evidence of severe respiratory impairment in the PACU would have a higher incidence of residual block compared to matched controls without CREs.
Methods

- Design: Case-control study
- All cases during the 1-year study period with the outcome of interest in the PACU (CRE) were identified
  - CRE:
    1) Upper airway obstruction requiring intervention
    2) Mild-mod (90-93% SpO$_2$) or severe (<90% SpO$_2$) hypoxemia on >3L NC/min not responsive to intervention
    3) Signs respiratory distress/impending ventilatory failure
    4) Patient requiring re-intubation
    5) Evidence of aspiration
- If CRE identified by PACU nursing, study investigator immediately contacted and TOF ratio quantified using acceleromyography

Murphy et al. Anesth Analg. 2008;107(1);130-137.
Murphy et al.-Results

- Data was collected on 7,459 patients undergoing GA during the 1-year period
- CREs identified in 61 patients (0.8%)
- Multiple logistic regression analysis revealed the only preoperative or intraoperative factor associated with CREs was residual block

<table>
<thead>
<tr>
<th></th>
<th>Critical respiratory event group</th>
<th>Control group</th>
<th>Difference (95% CI)</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Train-of-four ratio</td>
<td>0.62±0.20</td>
<td>0.98±0.07</td>
<td>-0.36(-0.43 to -0.30)</td>
<td>&lt;0.0001‡</td>
</tr>
<tr>
<td>Degree of NM Blockade(^b)</td>
<td>Acceptable</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4(9.5%)</td>
<td>38(90.5%)</td>
<td>-81.0%(-90 to -66)</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td>Mild-to-moderate</td>
<td>7(9.5%)</td>
<td>4(9.5%)</td>
<td>7.1%(-9 to 24)</td>
<td>&lt;0.366*</td>
</tr>
<tr>
<td>Severe</td>
<td>31(73.8%)</td>
<td>0(0%)</td>
<td>73.8%(59 to 85)</td>
<td>&lt;0.0001*</td>
</tr>
</tbody>
</table>

\( \dagger \) Indicates significance level was corrected for multiple comparisons.

Murphy et al. *Anesth Analg.* 2008;107(1);130-137.
Hypothesis: If AMG reduces the frequency of residual NMB, it should also reduce the incidence of associated adverse respiratory events.

- 185 patients randomized to AMG group (quantitative monitor) or a control group (standard PNM-qualitative monitor).
- TOF group: Extubation when standard criteria met + no fade TOF.
- AMG group: Extubation when standard criteria met + TOF ratio > 0.8.
- During transport to PACU and in PACU: Examined for hypoxemia + airway obstruction.
## Murphy et al.-Results

<table>
<thead>
<tr>
<th>Degree of neuromuscular blockade*</th>
<th>Acceleromyography Group</th>
<th>Conventional TOF Group</th>
<th>Difference (99% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acceptable recovery</td>
<td>85 (95.5%)</td>
<td>63 (70%)</td>
<td>25.5% (12.0 to 39.7%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Moderate</td>
<td>4 (4.5%)</td>
<td>15 (16.7%)</td>
<td>-12.2% (-25.2 to -0.4%)</td>
<td>0.014</td>
</tr>
<tr>
<td>Severe</td>
<td>0 (0%)</td>
<td>12 (13.3%)</td>
<td>-13.3% (-25.1 to -6.0%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Acceleromyography Group</th>
<th>Conventional TOF Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>89</td>
<td>90</td>
</tr>
<tr>
<td>No. with episodes of SpO₂ 90-93% During Transport</td>
<td>9 (10.1%)</td>
<td>7 (18.9%)</td>
</tr>
<tr>
<td>No. with episodes of SpO₂ &lt;90% During Transport</td>
<td>0 (0%)</td>
<td>10 (21.1%)</td>
</tr>
<tr>
<td>Lowest SpO₂ During Transport, %</td>
<td>96 (90-100)</td>
<td>94 (78-100)</td>
</tr>
<tr>
<td>No. requiring airway maneuver during transport</td>
<td>0 (0%)</td>
<td>10 (11.1%)</td>
</tr>
</tbody>
</table>

Objective: To determine the incidence of POPC following the use of pancuronium, atracurium, and vecuronium and to examine the effect of RNMB in the PACU on the incidence of POPC

Methods
- 691 patients (abdominal, gynecologic, or orthopedic) randomized to receive pancuronium, atracurium, or vecuronium
- NM management standardized; all patients reversed
- TOF ratios measured in PACU with MMG and patients examined for signs of muscle weakness
- Patients examined over post-operative day (POD) 1-6 for POPC
  - Pneumonic infiltrate or atelectasis on chest X-ray (CXR)
## Berg et al-Results

<table>
<thead>
<tr>
<th></th>
<th>Pancuronium (n=266)</th>
<th>Attracurium or Vecuronium (n=450)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of Patients</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOF≥0.7</td>
<td>167</td>
<td>426</td>
</tr>
<tr>
<td>TOF&lt;0.7</td>
<td>59</td>
<td>74</td>
</tr>
<tr>
<td><strong>Patients with POPC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOF≥0.7</td>
<td>8</td>
<td>23</td>
</tr>
<tr>
<td>TOF&lt;0.7</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td><strong>n</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>%</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOF≥0.7</td>
<td>4.8</td>
<td>5.4</td>
</tr>
<tr>
<td>TOF&lt;0.7</td>
<td>16.9*</td>
<td>4.2</td>
</tr>
</tbody>
</table>

*P<0.02
Residual Neuromuscular Blockade Affects Postoperative Pulmonary Function

Gopalaiah Venkatesh Kumar, M.B.B.S., D.N.B.,* Anita Pramod Nair, M.B.B.S., D.N.B.,† Hanuman Srinivasa Murthy, M.B.B.S., M.D.,‡ Koppa Ramegowda Jalaja, M.B.B.S., D.N.B.,‡ Karnate Ramachandra, M.B.B.S., M.D.,‡ Gundappa Parameshwara, M.B.B.S., M.D.‡
The influence of residual neuromuscular block on the incidence of critical respiratory events. A randomized, prospective, placebo-controlled trial

- 114 patients undergoing orthopedic procedures under GA randomized to reversal (neostigmine) or placebo (saline)
- Neostigmine monitored with TOF-Watch
- Placebo group monitored with a standard PNS

Results
- Placebo group -TOF ratio 0.7 in PACU
- Neostigmine group -TOF ratio 1.0 in PACU
- 45 (40%) patients had hypoxemia (SpO2 < 93%)
  - 29 patients placebo group
  - 16 patients neostigmine group (P=0.021)
Residual neuromuscular block as a risk factor for critical respiratory events in the PACU

- Prospective cohort study conducted over 3 weeks
- 202 patients arriving in PACU were examined for PRNB (TOF < 0.9)

Results
- Incidence of PRNB 30%
- Patients with PRNB had higher incidence of:
  - CRE (51 vs. 16%)
  - airway obstruction (10% vs. 2%)
  - mild-mod hypoxemia (23% vs. 4%)
  - severe hypoxemia (7% vs. 1%)
  - respiratory failure (8% vs. 1%)
  - inability to breathe deeply (38% vs. 12%)
  - muscular weakness (16% vs. 1%)
Residual Neuromuscular Block in the Elderly: Incidence and Clinical Implications

- Data prospectively collected on 150 younger (18-50) and 150 elderly (>70) patients
- TOF ratios measured on arrival to PACU
- Patients examined for adverse respiratory events from tracheal extubation until hospital discharge
- Postoperative muscle weakness quantified using a standardized exam, and PACU and hospital lengths of stay were determined
Results-continued

- Incidence of PRNB was 57.7% in elderly and 30.0% in younger patients (P< 0.001).
- Airway obstruction, hypoxemic events, signs and symptoms of muscle weakness, postoperative pulmonary complications, and increased PACU and hospital lengths of stay were observed more frequently in the elderly (all P < 0.01).
- In elderly cohort, no differences in preop or introp characteristics between those with and without PRNB.
- However, the majority of adverse events were observed in patients with PRNB.
Conclusions: Residual Neuromuscular Blockade and Adverse Respiratory Outcomes

- Databased investigations suggest an association between residual blockade and major adverse respiratory morbidity and mortality.
- Clinical studies have demonstrated that incomplete neuromuscular recovery in the PACU results in adverse respiratory events.
- Methods to reduce the risk of postoperative residual blockade are needed in order to optimize patient recovery and improve patient safety.